000295923 001__ 295923
000295923 005__ 20241221165702.0
000295923 0247_ $$2doi$$a10.1016/j.cgh.2024.11.019
000295923 0247_ $$2pmid$$apmid:39694204
000295923 0247_ $$2ISSN$$a1542-3565
000295923 0247_ $$2ISSN$$a1542-7714
000295923 037__ $$aDKFZ-2024-02736
000295923 041__ $$aEnglish
000295923 082__ $$a610
000295923 1001_ $$aGuo, Lanwei$$b0
000295923 245__ $$aGlobal Distribution of Colorectal Cancer Staging at Diagnosis: An Evidence Synthesis.
000295923 260__ $$aNew York, NY$$bElsevier Science$$c2024
000295923 3367_ $$2DRIVER$$aarticle
000295923 3367_ $$2DataCite$$aOutput Types/Journal article
000295923 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1734705861_2136$$xReview Article
000295923 3367_ $$2BibTeX$$aARTICLE
000295923 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000295923 3367_ $$00$$2EndNote$$aJournal Article
000295923 500__ $$aepub
000295923 520__ $$aStage at diagnosis is a key prognostic factor for colorectal cancer (CRC) survival. We aimed to assess the global distribution of CRC staging at diagnosis using population-based or hospital-based registry data.We systematically searched in MEDLINE and Embase from their inception until 6 December 2023. Grey literature was searched through published cancer reports. Studies from population-based or hospital-based cancer registries reporting the stage distribution of diagnosed CRC were included. We extracted stage-specific proportions among patients with CRC based on TNM, SEER, or Dukes staging systems. Subgroup analyses by sex, age, tumor site, calendar period, and status of population-based screening were performed. Correlations between the Human Development Index (HDI), Socio-Demographic Index (SDI), and the distant metastatic CRC proportion were also evaluated.84 eligible studies/reports from 46 countries were analyzed, covering 3.8 million patients. Among 36 countries included in the main analysis, the most recent distant metastatic CRC proportions varied from 16.2% in Puerto Rico to 28.2% in Oman and Latvia, with a median (interquartile range) of 23.7% (21.8%-26.3%). Higher metastatic proportions were observed in younger patients, those with colon cancer, and those without screening implementation, with no apparent difference between males and females. Over time, some countries/regions, such as Southern Portugal (36.5% in 2000 to 22.2% in 2016), showed declining proportions of metastatic CRC, while others remained stable (e.g., Austria, Belgium) or increased (e.g., United States, Slovenia, Spain). Higher HDI and SDI were correlated with lower proportions of distant metastatic CRC (HDI: ρ=-0.48; SDI: ρ=-0.26).Global disparities in CRC staging exist, indicating a need for targeted interventions to enhance early detection and management, especially in high-metastasis areas.
000295923 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000295923 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000295923 650_7 $$2Other$$acolorectal cancer
000295923 650_7 $$2Other$$astage
000295923 650_7 $$2Other$$asystematic review
000295923 7001_ $$aWang, Le$$b1
000295923 7001_ $$aCai, Lin$$b2
000295923 7001_ $$aZhang, Yuelun$$b3
000295923 7001_ $$aFeng, Xiaoshuang$$b4
000295923 7001_ $$aZhu, Chenxin$$b5
000295923 7001_ $$aGao, Wendong$$b6
000295923 7001_ $$0P:(DE-HGF)0$$aCardoso, Rafael$$b7
000295923 7001_ $$aYang, Haiyan$$b8
000295923 7001_ $$aDai, Min$$b9
000295923 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$udkfz
000295923 7001_ $$aChen, Hongda$$b11
000295923 773__ $$0PERI:(DE-600)2102638-5$$a10.1016/j.cgh.2024.11.019$$gp. S1542356524011042$$pnn$$tClinical gastroenterology and hepatology$$vnn$$x1542-3565$$y2024
000295923 909CO $$ooai:inrepo02.dkfz.de:295923$$pVDB
000295923 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000295923 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000295923 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000295923 9141_ $$y2024
000295923 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN GASTROENTEROL H : 2022$$d2023-10-25
000295923 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000295923 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000295923 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000295923 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000295923 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000295923 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000295923 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000295923 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN GASTROENTEROL H : 2022$$d2023-10-25
000295923 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000295923 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000295923 980__ $$ajournal
000295923 980__ $$aVDB
000295923 980__ $$aI:(DE-He78)C070-20160331
000295923 980__ $$aI:(DE-He78)HD01-20160331
000295923 980__ $$aUNRESTRICTED